(0.09%) 5 521.75 points
(0.14%) 39 899 points
(0.16%) 19 783 points
(-0.06%) $81.58
(0.68%) $2.83
(-0.27%) $2 338.00
(0.10%) $29.56
(0.51%) $1 006.90
(0.04%) $0.932
(-0.08%) $10.53
(0.01%) $0.788
(-0.84%) $87.25
-0.41% $ 2.42
Live Chart Being Loaded With Signals
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation...
Stats | |
---|---|
Dzisiejszy wolumen | 488 683 |
Średni wolumen | 415 883 |
Kapitalizacja rynkowa | 133.48M |
EPS | $-0.360 ( Q1 | 2024-05-06 ) |
Następna data zysków | ( $-0.360 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.460 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Szela Mary T | Buy | 25 000 | Stock Option (Right to Buy) |
2024-06-20 | Boehm Rainer J. | Buy | 25 000 | Stock Option (Right to Buy) |
2024-06-20 | Schade Christian S | Buy | 25 000 | Stock Option (Right to Buy) |
2024-06-20 | Mendlein John | Buy | 25 000 | Stock Option (Right to Buy) |
2024-06-20 | Levy Elliott M. | Buy | 25 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
81.67 |
Last 91 transactions |
Buy: 33 330 177 | Sell: 8 388 320 |
Wolumen Korelacja
Omega Therapeutics, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ISSC | 0.87 |
DLHC | 0.865 |
POAI | 0.861 |
EZGO | 0.856 |
MPAA | 0.851 |
RPTX | 0.847 |
MBIO | 0.846 |
EYEN | 0.846 |
HDSN | 0.841 |
RCKT | 0.84 |
10 Najbardziej negatywne korelacje | |
---|---|
CENX | -0.855 |
GRIN | -0.841 |
GERN | -0.837 |
SMTC | -0.834 |
PPTA | -0.833 |
NN | -0.833 |
CURI | -0.832 |
GALT | -0.83 |
LABP | -0.825 |
STAA | -0.824 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Omega Therapeutics, Inc. Korelacja - Waluta/Towar
Omega Therapeutics, Inc. Finanse
Annual | 2023 |
Przychody: | $3.09M |
Zysk brutto: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2023 |
Przychody: | $3.09M |
Zysk brutto: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2022 |
Przychody: | $2.07M |
Zysk brutto: | $-3.12M (-150.36 %) |
EPS: | $-2.14 |
FY | 2021 |
Przychody: | $144 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej